Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pon

(1)

CORRECTION

Correction: Real-life data on potential

drug-drug interactions in patients with chronic

hepatitis C viral infection undergoing antiviral

therapy with interferon-free DAAs in the PITER

Cohort Study

Loreta A. Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, Anna Linda Zignego,

Monica Monti, Andrea Gori, Alessandro Soria, Giovanni Raimondo, Roberto Filomia,

Alfredo Di Leo, Andrea Iannone, Marco Massari, Romina Corsini, Roberto Gulminetti,

Alberto Gatti Comini, Pierluigi Toniutto, Denis Dissegna, Francesco Paolo Russo,

Alberto Zanetto, Maria Grazia Rumi, Giuseppina Brancaccio, Elena Danieli, Maurizia

Rossana Brunetto, Liliana Elena Weimer, Maria Giovanna Quaranta, Stefano Vella,

Massimo Puoti

The graph that appears as

Fig 2A

is incorrectly duplicated in

Fig 2B

. Please see the corrected

Fig 2

here.

PLOS ONE |https://doi.org/10.1371/journal.pone.0190803 January 2, 2018 1 / 2

a1111111111

OPEN ACCESS

Citation: Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, et al. (2018) Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS ONE 13(1): e0190803.https://doi.org/10.1371/journal. pone.0190803

Published: January 2, 2018

Copyright:© 2018 Kondili et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

(2)

Reference

1. Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, et al. (2017) Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS ONE 12(2): e0172159.https://doi.org/10. 1371/journal.pone.0172159PMID:28245248

Fig 2. Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected patients. Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver disease (B). DAA regiments and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.

https://doi.org/10.1371/journal.pone.0190803.g001